T he potent cardioprotection induced by brief periods of ischemia before sustained ischemia is termed ischemic preconditioning (IP). Previous studies [1] [2] [3] [4] have exhibited some possible mediators of IP-derived cardioprotection, suggested to link with protein kinase C (PKC). 3, 4 On the other hand, a brief preconditioning ischemia also induces a synchronized increase of the myocardial cyclic AMP (cAMP) level. 5 Furthermore, we and others 5, 6 have reported that brief preischemic exposure to ␤-agonists, an adenylate cyclase activator, phosphodiesterase type III inhibitors, or a cell-permeable cAMP analogue, all of which cause rapid activation of protein kinase A (PKA), also protects the myocardium in vivo independently of PKC. However, little is known about the direct contribution of PKA to infarct limitation by IP and the associated subcellular mechanisms. Some recent studies have demonstrated that an increase of cAMP followed by activation of PKA causes temporary inhibition of small GTPase RhoA 7, 8 and its downstream Rho-kinase, 7 playing major roles in enhancement of actin cytoskeleton formation followed by chemotactic migration, platelet activation, and cytokinesis. 7, 9 Therefore, we hypothesized that transient preischemic activation of PKA may also cause IP-induced infarct limitation through the inhibition of Rho-kinase after the onset of sustained ischemia. This study was designed to test this hypothesis in vivo.
Methods
All procedures were performed in conformity with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, 1996 revision) and were approved by the Osaka University Committee for Laboratory Animal Use.
Instrumentation
As described previously, 10 beagle dogs (Oriental Yeast; Osaka, Japan) weighing 9 to 14 kg were anesthetized with sodium pentobarbital (30 mg/kg IV) and connected to an extracorporeal bypass tube. In all experiments, the average control values of mean aortic blood pressure (ABP), heart rate (HR), and arterial blood pO 2 were 101Ϯ2.3 mm Hg, 127Ϯ2.4/minute, and 108Ϯ3.8 mm Hg, respectively. Both ABP and HR were measured continuously during the experiment. Figure 1 shows the study protocol. After hemodynamic stabilization, 176 dogs underwent 90 minutes of ischemia and 6 hours of reperfusion with or without 1 or more of the following interventions: (1) 5-minute coronary occlusion followed by 25-minute reperfusion just before sustained ischemia (IP), (2) intracoronary administration of the potent PKC activator phorbol 12-myristate 13-acetate (PMA, Sigma; 0.62 ng/kg per min), or (3) an intravenous administration of the cell-permeable cAMP analogue dibutyrylcAMP (db-cAMP, Sigma; 5 mg/kg over 5 minutes), in combination with (4) intracoronary injection of a selective PKC inhibitor, GF109203X (Calbiochem; 40 g/kg per min) or 1 of 2 selective PKA inhibitors (H89 6, 11 [Sigma; 1.35 g/kg per min] or the Rp-isomer of cAMP 12 [Rp-cAMP, Calbiochem; 45 g/kg per min]) or (5) infusion of vehicle (at a rate of 0.0167 mL/kg per min) (control, vehicle, IP, IPϩvehicle, IPϩH89, IPϩRp-cAMP, PMA, PMAϩH89, PMAϩRp-cAMP, Db-cAMP, DbcAMPϩH89, Db-cAMPϩRp-cAMP, Db-cAMPϩGF109203X [GFX], PMAϩDb-cAMP, H89, Rp-cAMP, and GFX groups, respectively; nϭ8 to 13 each).
Experimental Protocols

Protocol 1: Infarct Size After Preconditioning
We used the same PMA or db-cAMP regimens that were used in our previous studies, 3, 6 which demonstrated potent infarct limitation in this model. The regimen of GF109203X infusion was the same as that used in our previous study 3 to blunt infarct limitation by IP and PMA.
Protocol 2: Infarct Size in the Inhibition Protocol During Ischemia
The lower part of Figure 1 shows the protocol. Sixty-six dogs underwent the same protocol for sustained ischemia-reperfusion with or without intracoronary administration of (1) 10 ) between the onset and 60 minutes of sustained ischemia (hydroxyfasudil-lower dose [LD], hydroxyfasudil, Y27632-LD, Y27632, cytochalasin-D, and ischemia-vehicle groups, respectively; nϭ10 to 12 each).
The higher doses of hydroxyfasudil and Y-27632 for intracoronary infusion were the highest doses that could not influence systemic hemodynamics during our preliminary study in this model (data not shown). Figure 2 shows the protocol. Ninety dogs were subjected to sustained myocardial ischemia according the same method as in protocol 1 with or without (1) IP, (2) preischemic administration of db-cAMP or PMA, (3) preischemic administration of H89, Rp-cAMP, or GF109203X, or (4) administration of hydroxyfasudil or Y27632 during ischemia (sham, control, PMA, Db-cAMP, ischemia-vehicle, hydroxyfasudil-LD, hydroxyfasudil, Y27632-LD, Y27632, DbcAMPϩRp-cAMP, IP, IPϩvehicle, IPϩH89, IPϩRp-cAMP, and IPϩGF109203X groups, respectively; nϭ4 or 5 each).
Protocol 3: Tissue Kinase Assay
We quickly sampled the myocardium in the target region (1) at the end of IP, PMA infusion, or db-cAMP infusion to assay PKA and (2) after 60-minute ischemia to assay Rho-kinase activity ( Figure 2 ). The sampled tissues were rapidly frozen in liquid nitrogen and stored at Ϫ80°C.
Measurements of Collateral Blood Flow, Risk Area, and Infarct Size
In protocols 1 and 2, we measured the myocardial collateral blood flow after 60 minutes of ischemia by a nonradioactive microsphere method and evaluated both the area at risk and the infarct size by dual staining, as described previously. 6,10 
Exclusion Criteria
To ensure that all of the animals included in the data analysis were healthy and were exposed to a similar extent of ischemia, the exclusion criteria described previously 10 regarding hemodynamism, excessive collateral flow, and lethal arrhythmia were used.
PKA and Rho-Kinase Assay
We assayed PKA and Rho-kinase activity as described previously 13 
Statistical Analysis
Results are expressed as meanϮSEM. Statistical analysis was performed by ANOVA with modified Bonferroni's post hoc test, and significance was defined at PϽ0.05.
Results
Mortality and Exclusions, Hemodynamic Parameters, Risk Area, and Collateral Blood Flow
Among the 242 dogs used in protocols 1 and 2, 55 dogs met the exclusion criteria of ventricular fibrillation or excessive myocardial collateral blood flow (Ͼ15 mL/100 g per min). Therefore, 187 dogs completed these protocols satisfactorily and were included in the data analysis (Table) . The changes of ABP and HR were comparable among the 23 groups throughout the experiment (data not shown), and the area at risk and collateral blood flow were also comparable (Table) . Figure 3 shows the infarct size for each group in protocol 1 (left) and protocol 2 (right). 
Infarct Size
PKA Activity During Preconditioning
In protocol 3, IP and db-cAMP activated PKA (267Ϯ22% and 288Ϯ34% of baseline, respectively; both PϽ0.05 versus sham). IP-derived PKA activation was inhibited by coadministration of H89 or Rp-cAMP (112Ϯ23% and 99Ϯ17%, respectively; both PϽ0.05 versus IPϩvehicle). We also confirmed that DbcAMP-derived PKA activation was cancelled by Rp-cAMP (121Ϯ22%, PϽ0.05 versus IPϩvehicle). Furthermore, we observed that 1 to 5 doses of H89 and Rp-cAMP only caused partial (189Ϯ29% and 175Ϯ29%, respectively) inhibition of PKA (Figure 4) , showing that the dose levels we used in this study were the minimum effective doses, which should eliminate the possibility of a nonspecific action in this model.
Rho-Kinase Activity During Ischemia
A 60-minute period of ischemia caused Rho-kinase activation (307Ϯ25% of baseline in the control group; PϽ0.05 versus sham), which was attenuated by IP or preischemic administration of db-cAMP (145Ϯ21% and 151Ϯ26%, respectively; PϽ0.05 versus control) but not by PMA (253Ϯ30%, PϽ0.05 versus sham). The IP-induced suppression of Rho-kinase activation was cancelled by Rp-cAMP (247Ϯ39%, PϽ0.05 versus IP) but not by GF109203X (161Ϯ34%, PϽ0.05 versus control) at the same dose as in protocol 1 ( Figure 5 ; left). Furthermore, administration of either hydroxyfasudil or Y27632 during sustained ischemia caused a dose-dependent decrease of Rho-kinase activation (199Ϯ36% and 205Ϯ33% in the hydroxyfasudil-LD and Y27632-LD groups, respectively; 134Ϯ21% and 135Ϯ20% in the hydroxyfasudil and Y27632 groups, respectively), which was significant (PϽ0.05 versus the ischemia-vehicle group) at the higher doses ( Figure 5 ; right).
Discussion
Triggers of IP: Involvements of cAMP, PKA, and ␤-Adrenoceptors
Single or repeated IP as well as repeated treatment with forskolin is reported to rapidly and transiently increase both myocardial cAMP level and tissue PKA activity. 5 We observed in this model that the intracoronary coadministration of different types of selective PKA antagonists blunted infarct Mortality, exclusion, area at risk, and collateral flow in each group in protocols 1 and 2. Data are expressed as meanϮSEM.
Profile of the Groups in Protocols 1 and 2
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limitation of IP, suggesting the involvement of PKA in the IP-derived cardioprotection. However, it remains unclear whether the ␤-adrenoceptor is involved in this response, despite the prominent role of the ␣ 1 -adrenoceptor in PKCmediated cardioprotection. 1, 5 Although a single exposure to brief ischemia or a ␤-agonist limits infarct size through ␤-adrenoceptor activation 5, 17 and repeated preischemic activation of the cAMP-PKA-dependent pathway is also modulated by ␤-adrenoceptor expression, 18 the contribution of this receptor in cardioprotection by repeated exposures remains unclear 5,17 because of PKA-induced rapid desensitization. 19 It is reported in other systems that the repeated IP might lead to cAMP accumulation and direct PKA activation independently of the ␤-adrenoceptor 5 through the inhibition of phosphodiesterase 5 or direct sensitization of adenylate cyclase. 20 However, we have documented preliminarily in the present model that the intracoronary coadministration of the selective ultra-short-acting ␤ 1 -adrenoceptor blocker landiolol 21 around the preconditioning ischemia (as in protocol 1) blunted the infarct limitation by IP used in this study (35.0Ϯ4.4%, nϭ7) as well as PKA inhibitors during IP, additionally suggesting the essential contribution of ␤ 1 -adrenoceptor activation to cause IP-induced PKA-dependent cardioprotection in this model. However, more studies might be expected to clarify these issues. On the other hand, IP leads to decreased cAMP accumulation during sustained ischemia, 22 but it is controversial whether this explains the cardioprotection afforded by preischemic activation of PKA. 5, 22 Enhancement of cAMP accumulation during sustained ischemia fails to block cardioprotection by IP. 22 Moreover, overexpression of ␤-adrenergic receptor kinase-1, which causes functional uncoupling of ␤-adrenoceptors, impairs ischemia-reperfusion injury, and this impairment is reversed by co-overexpression of ␤-adrenergic receptor kinase-1 inhibitor. 23 
Role of PKA and PKC
Manganello et al 8 demonstrated that PKA primarily phosphorylates the switch-I region of G-␣ 13 (an essential G-protein for signaling to RhoA stimulated by G-proteincoupled receptors 8 ) and inhibits its binding with G-␤-␥, which subsequently leads to the inhibition of G-␣ 13 turnover and inactivation of RhoA.
Although PKC 24 or its downstream kinase 25 has been reported to induce actin assembly through activation of PKC-potentiated phosphatase inhibitor and Rho-kinase, another study found that both PKC and the downstream Src tyrosine kinase rapidly deactivate RhoA through p190 and cause actin disassembly. 26 The PKC-Src/Lck pathway was reported to play a role in cardioprotection by IP. 4 However, preischemic PKC activation had little influence on IPinduced Rho-kinase inhibition in this study, showing the limited contribution of PKC to this pathway. Furthermore, we have reported 27 that Src/Lck tyrosine kinase is not involved in the infarct limitation by IP in this model. Although it did not 
Cardioprotection by Rho-Kinase Inhibition
Because inhibition of Rho-kinase directly relaxes vascular smooth muscle, 9,13,29 it may increase regional myocardial blood flow at sites of major coronary artery stenosis (without any inotropic or chronotropic effect) by dilating the abnormal artery. 29 However, this study showed that Rho-kinase inhibition during sustained ischemia exerted cardioprotection without altering hemodynamics, even after all of the dogs with excessive collateral flow were excluded from analysis. Therefore, the infarct-limiting mechanism that involves Rho-kinase inhibition could be independent of either a change in systemic hemodynamics or the recruitment of collateral blood flow. Rho-kinase has multiple effects on the cardiovascular system, which dominantly represent those of RhoA, 9 because of inhibition of myosin phosphatase and activation of the ERM family (ezrin, radixin, or moesin) or adducin. 9 Importantly, Rho-kinase plays a major role in stress fiber formation, focal adhesion, migration, and cytokinesis through activation of the ERM family and thus can enhance cardiac damage in acute ischemia. The potent infarct limitation by cytochalasin-D that mimicked PKA-Rho-kinase-mediated cardioprotection suggests that deactivation of stress fiber polymerization is a major part of this cardioprotective mechanism.
In fact, the effect of changes to the actin cytoskeleton on infarct size has been controversial, because a previous study revealed that targeted deletion of the internal actin disruptor caused the exacerbation of ischemic damage and was rescued by cytochalasin-D, 30 whereas another study revealed that cytochalasin-D abolished the infarct limitation by IP. 31 However, inhibition of Rho and Rho-kinase has also been reported to activate endothelial NO synthase, 15 K ATP channels, 32 and 5Ј-nucleotidase, 33 all of which have been reported to protect the myocardium against ischemia-reperfusion injury. Additional studies are needed to clarify such issues, because these controversies are likely to be attributable to the differences in experimental design and in the critical time window for the contribution of each factor.
Inhibition of Rho-kinase has also been shown to attenuate the production of superoxide, reduce the generation of monocyte chemoattractant protein-1 or plasminogen activator inhibitor-1, and inhibit the activation of macrophages, neutrophils, and platelets, all of which finally lead to the inhibition of stress-induced regional inflammatory responses and diminished myocardial ischemia-reperfusion injury. 9 IP has been reported to modulate most of these factors, 1,2 additionally supporting our present results. Accordingly, our preliminary data in the same model indicate that the intracoronary infusion of Y27632 (3 g/kg per min) for 30 minutes just after reperfusion also reduced infarct size (22.3Ϯ4.8%, nϭ7) as expected. However, the underlying mechanism and its association with the IP-induced preischemic PKA activation should be further elucidated.
In conclusion, although additional studies will be needed before these can be used for the development of novel, safe, and effective therapies, inhibition of Rho-kinase during ischemia, long-term inhibition of Rho-kinase pharmacologically or genetically, or repeated short-term activation of ß-adrenoceptors or PKA may also be useful. 
